Trinity Biotech (TRIB) now received full regulatory approval for the commencement of upstream manufacturing activities for its flagship World Health Organization prequalified Uni-Gold(TM) HIV rapid test under the Company’s offshored and outsourced production model. This latest approval from the in-country healthcare product regulatory authority marks the final major regulatory milestone required to fully implement Trinity Biotech’s new offshore & outsourced manufacturing model for Uni-Gold HIV, enabling the Company to transition some upstream processes to a more cost-efficient and highly scalable offshore manufacturing platform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity achieves IFCC Gold Classification for Premier Hb9210 HbA1c Analyser
- Trinity Biotech files to sell 55.89M American depositary shares
- Trinity Biotech Restructures Perceptive Debt With New $5 Million Term Loan and Expanded ADS Conversion Rights
- Trinity Biotech enters series of agreements with Perceptive Advisors funds
- Trinity Biotech Files Mid‑2025 Unaudited Interim Results with U.S. Regulators